Blood transfusion

Global Blood Transfusion Set Market Expected to Rebound with 3.0% CAGR, Reaching $591 Million by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 29, 2023
Health, Other Health, Male, IV, Prevalence, ICU Medical, Pump, Baxter, Cancer, Luer, Domination, Research, BD (company), Blood transfusion, Chronic, BD, Medical device, Pharmaceutical industry, Alaris

In 2023, the global blood transfusion set market reported a total value of $480.1 million, experiencing a modest decline of 3.5% from the $464.1 million recorded in 2022.

Key Points: 
  • In 2023, the global blood transfusion set market reported a total value of $480.1 million, experiencing a modest decline of 3.5% from the $464.1 million recorded in 2022.
  • Currently, market leaders in the global blood transfusion set market include Becton Dickinson (BD), Baxter, and ICU Medical.
  • Rebound Expected: The global blood transfusion set market is projected to rebound with a CAGR of 3.0%, reaching a valuation of $591 million, following a 3.5% decline in 2023.
  • Dominant Players: Key players such as Becton Dickinson (BD), Baxter, and ICU Medical currently dominate the global blood transfusion set market.

Critical Nursing Shortage Drives 117% Customer Spike for UbiSim Immersive Virtual Reality Simulation Training Platform

Retrieved on: 
Tuesday, September 12, 2023
Technology, Nursing, Hospitals, Telemedicine, Virtual Medicine, Software, Other Education, Training, Health, Education, Madera Community College, SVT, NLN, Communication, Employment, Pneumonia, Pallor, University, College, Heart failure, MSN, Sheridan College, HIV, EKG, Anxiety, ADHD, World Health Organization, Multimedia, Shingles, Language, VR, FIU College of Nursing and Health Sciences, Jaundice, Student, Hospital, National League, Blood transfusion, Vital signs, Patient, Champaign–Urbana metropolitan area, Diversity, National League for Nursing, Virtual reality, Faculty, RN, Diagnosis, Sickle cell disease, DEI, Next Generation, University of Manitoba, National Harbor, Maryland, CHSE

View the full release here: https://www.businesswire.com/news/home/20230912362852/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230912362852/en/
    Screenshot from a UbiSim immersive virtual reality (VR) simulation for HIV & Shingles: Learners implement nursing interventions for a patient newly diagnosed with shingles and HIV.
  • The UbiSim platform is a complete simulation lab that provides nursing trainees with virtual access to a variety of clinical situations.
  • UbiSim lets faculty choose from 50-plus existing training scenarios created in collaboration with nursing educators and simulation experts.
  • The footprint for its VR training platform for nursing has expanded to nine countries, including the U.S. and Canada.

Red Cross announces national blood shortage

Retrieved on: 
Monday, September 11, 2023
Vicar Hope Foundation, American Red Cross, Tropical Storm Lee, Travel, Blood, Season, Cancer, Black, Plasma, Student, Hospital, Blood transfusion, Patient, Social isolation, International Red Cross and Red Crescent Movement, Sickle cell disease, Red, World Blood Donor Day, 2019 Sport Clips Haircuts VFW 200, Red Cross, African Americans, VIP, Disease, Medical device

WASHINGTON, Sept. 11, 2023 /PRNewswire/ -- The American Red Cross national blood supply has fallen to critically low levels—dropping nearly 25%-- since early August, and potentially threatening the medical care of patients with an emergency need for blood, or those living with critical conditions such as cancer and sickle cell disease and who depend on lifesaving blood transfusions. Back-to-back months of worsening climate-driven disasters have further strained the blood supply, resulting in blood drive cancelations and reducing much needed blood and platelet donations in affected areas.

Key Points: 
  • Back-to-back months of worsening climate-driven disasters have further strained the blood supply, resulting in blood drive cancelations and reducing much needed blood and platelet donations in affected areas.
  • To make an appointment to give blood or platelets, donors can use the Red Cross Blood App, visit RedCrossBlood.org or call 1-800-RED CROSS (1-800-733-2767).
  • Joined by Blood is a fall activation of the Red Cross Sickle Cell Initiative which represents the powerful connection between blood donors and patients, since 1 in 3 African American blood donors are a match for people with sickle cell disease.
  • In thanks for helping to replenish the blood supply this month, all who come to give blood, platelets or plasma Sept. 1-18 will receive a limited-edition Red Cross T-shirt, while supplies last.

magAssist's NyokAssist™️ granted Designation by the FDA as a Breakthrough Device

Retrieved on: 
Monday, August 21, 2023
Intervention, Rotation, FDA, Bleeding, Regulation of tobacco by the U.S. Food and Drug Administration, Blood transfusion, Hemolysis, Research, Risk, Patient, Food, Medical device

SUZHOU, China, Aug. 21, 2023 /PRNewswire/ -- Recently, magAssist's NyokAssist™ Interventional Ventricular Assist Device (hereinafter referred to as NyokAssist™), has been granted designation as a breakthrough device by the U.S. Food and Drug Administration (FDA) in Breakthrough Device Program.

Key Points: 
  • SUZHOU, China, Aug. 21, 2023 /PRNewswire/ -- Recently, magAssist's NyokAssist™ Interventional Ventricular Assist Device (hereinafter referred to as NyokAssist™), has been granted designation as a breakthrough device by the U.S. Food and Drug Administration (FDA) in Breakthrough Device Program.
  • This recognition from FDA has reaffirmed magAssist's unwavering dedication to technology innovation in the area of artificial heart in medical device industry.
  • Receiving Breakthrough Designation for the NyokAssist™️ represents a major milestone for magAssist, showing that the device stands at the forefront of innovation.
  • The company remains committed to advancing medical technology through continued innovation, research and patient-centric solutions that create values for patients healthcare as well as to medical device industry.

Regional Hospitals Choose The Blood Connection as Sole Blood Provider

Retrieved on: 
Monday, July 24, 2023
Trident, Partnership, Health, Cancer, Organization, Doctors Hospital, Hospital, Blood transfusion, Patient, Blood, TBC, World Blood Donor Day, Grand Strand Medical Center, Trauma, Medical device, Pharmaceutical industry

AUGUSTA, Ga. and SAVANNAH, Ga. and MYRTLE BEACH, S.C. and CHARLESTON, S.C., July 24, 2023 /PRNewswire/ -- The Blood Connection (TBC), an independently managed, non-profit community blood center is announcing a new partnership to serve as the sole blood provider for regional hospitals across Georgia and South Carolina within a large healthcare system. This partnership builds upon existing relationships with these hospitals and makes TBC the sole provider for five more hospitals. TBC was chosen to serve one of the nation's leading providers of healthcare services because of its proven ability to provide a ready and stable blood supply for local hospital partners, even throughout the pandemic. TBC's reliability and consistency helps to ensure a robust healthcare system for trauma victims and the many patients who rely on blood transfusions.

Key Points: 
  • This partnership builds upon existing relationships with these hospitals and makes TBC the sole provider for five more hospitals.
  • TBC has extended its partnership as the sole provider for Trident Regional Medical Center, Summerville Medical Center, Colleton Medical Center, and Grand Strand Medical Center.
  • TBC, formerly known as Carolina-Georgia Blood Center, has served as a non-profit 501(c)(3) community blood center for 60 years.
  • The blood center was originally formed to be a blood provider for small hospitals in Georgia and South Carolina, before it eventually grew to become The Blood Connection.

Suburban Propane Boosts Sickle Cell Awareness Through Blood Drive Event with The American Red Cross and Eric LeGrand

Retrieved on: 
Tuesday, June 20, 2023
American Red Cross, Partnership, Anti-transglutaminase antibodies, Life, COVID-19, Electricity, Carbon, Propane, Eric LeGrand, Patient, Blood, Natural gas, International Red Cross and Red Crescent Movement, Sickle cell disease, SPH, World Blood Donor Day, Blood transfusion, Team, NYSE, African Americans, Medical device, Black

Eric LeGrand attended the event, which included a blood drive, and spoke about the need for more blood donations to fight sickle cell disease.

Key Points: 
  • Eric LeGrand attended the event, which included a blood drive, and spoke about the need for more blood donations to fight sickle cell disease.
  • "Suburban Propane is honored to team up with our longtime partners at the American Red Cross and with hometown hero, Eric LeGrand, to increase awareness for such an important cause," said Nandini Sankara, Spokesperson, Suburban Propane.
  • "We appreciate Suburban Propane and Eric LeGrand helping bring awareness to the need for blood donation to help Sickle Cell patients with their treatment."
  • "It is great to see Suburban Propane and the American Red Cross team up to host a blood drive in Fairfield and raise awareness for sickle cell disease," said Fairfield Mayor William Galese."

ImpactLife celebrates World Sickle Cell Awareness Day

Retrieved on: 
Monday, June 19, 2023
Juneteenth, Sickle cell disease, Sickle Cell Disease Association of America, Antibody, Pain, Blood transfusion, Patient, Blood, Glass, Anti-transglutaminase antibodies, Vaccine

The Juneteenth Federal holiday celebrating the emancipation of enslaved people in the United States is also recognized by the American Sickle Cell Disease Association as a day to raise awareness of the genetically inherited disease and its disproportionate impact on people of African descent.

Key Points: 
  • The Juneteenth Federal holiday celebrating the emancipation of enslaved people in the United States is also recognized by the American Sickle Cell Disease Association as a day to raise awareness of the genetically inherited disease and its disproportionate impact on people of African descent.
  • Patients with Sickle Cell Disease frequently receive transfusions of red blood cells to help treat symptoms of a sickle cell crisis.
  • Tiffani Jackson, a patient living with sickle cell disease, describes the pain of a sickle cell crisis and the relief a blood transfusion can bring:
    “It’s like being stabbed with pieces of broken glass, and that feeling does not go away after taking pain medicine.
  • With more frequent blood transfusions, patients with sickle cell disease can develop antibodies that are directed against red blood cell antigens, a process called alloimmunization.

Cerus Corporation Celebrates World Blood Donor Day 2023

Retrieved on: 
Wednesday, June 14, 2023
Health, Hospitals, Other Health, General Health, Pharmaceutical, Cardiology, Biotechnology, World Blood Donor Day, Cancer, World Health Assembly, Plasma, Corporation, Blood transfusion, Patient, Blood, CERS, WHO, World Health Organization, Medical device, Cerus Corporation

Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2023.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2023.
  • In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply.
  • At Cerus, we are focused on enabling both blood safety and availability through technology innovation, including expansion of donor eligibility when feasible,” Greenman continued.
  • “Whether for daily transfusion requirements or pandemic preparedness, the blood supply depends on the generosity of donors every single day.”
    In recognition of World Blood Donor Day, Cerus will host a blood drive at company headquarters and encourages everyone to participate in supporting blood product availability in their local communities.

New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Retrieved on: 
Friday, June 9, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Eculizumab, Arm, Hemolysis, AE, European Hematology Association, SC, Infection, Aes, Quality of life, Roche, TA, Chlorine, ROG, RO, Kidney disease, Anemia, EHA, PNH, Thrombus, Blood transfusion, Safety, Caregiver, Fatigue, Disease, Pharmaceutical industry, Medical device, Genentech

Crovalimab has been engineered to be recycled within the bloodstream, enabling sustained complement inhibition through low-dose, subcutaneous (SC) administration every four weeks.

Key Points: 
  • Crovalimab has been engineered to be recycled within the bloodstream, enabling sustained complement inhibition through low-dose, subcutaneous (SC) administration every four weeks.
  • Additionally, 65.7% (95% CI: 56.9, 73.5) achieved transfusion avoidance (TA) from baseline to week 25 with crovalimab and 68.1% (95% CI: 55.7, 78.5) with eculizumab.
  • The results from the COMMODORE 1 study indicate that crovalimab maintained disease control in people switching from currently approved complement inhibitors.
  • Global Phase III data from the COMMODORE 1 and 2 studies in PNH will be submitted to regulatory authorities around the world.

United States Infusion Therapy Market Analysis & Forecasts, 2019-2022 & 2023-2029: Infusion Pumps, Intravenous Sets, Needless Connectors, Stopcocks, Intravenous Filters & Blood Transfusion Devices - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 8, 2023
Pharmaceutical, Health, Medical Devices, Infusion, IV, FDA recall policies, Pump, Baxter, COVID-19, Texas Homecare, BD (company), Russian Industrial Leaders Index, CareFusion, Blood transfusion, Flow control, Intravenous therapy, Market, SWOT, Acquisition, SCSI Peripheral Device Type, ICU Medical, Mergers and acquisitions, Infusion pump, Growth, Patient, Stopcock, FDA, Disruptive innovation, Needleless connector, Medical device, Pharmaceutical industry, Medical imaging, Modularity

The "United States Infusion Therapy Market Size, Share & COVID-19 Impact Analysis 2023-2029 | MedSuite | Includes: Infusion Pumps, Intravenous Sets, Needless Connectors, Stopcocks, Intravenous Filters & Blood Transfusion Devices" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Infusion Therapy Market Size, Share & COVID-19 Impact Analysis 2023-2029 | MedSuite | Includes: Infusion Pumps, Intravenous Sets, Needless Connectors, Stopcocks, Intravenous Filters & Blood Transfusion Devices" report has been added to ResearchAndMarkets.com's offering.
  • The Infusion Therapy Device Market in the United States had a valuation of $3 billion in 2022.
  • The full report suite on the U.S. Market for Infusion Therapy Devices includes extensive analysis on the following segments: Infusion Pump Market, Intravenous Set Market, Needleless Connector Market, Stopcock Market, Intravenous Filter Market, and the Blood Transfusion Market.
  • The infusion therapy device market, being mature and stable, is expected to witness limited growth in unit sales.